Page 9 - Ongoing Phase News Today

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. (Nasdaq: XLRN), a publicly traded biopharmaceutical company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share ...

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful...

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful...

Chickasaw Journal E-Edition Delivery Are you a Chickasaw Journal subscriber? Sign up to view our weekly e-editions each Wednesday with just a click.  Itawamba Times E-Edition Delivery Are you an Itawamba Times subscriber? Sign up to view our weekly e-editions each Wednesday with just a click. Monroe Journal E-Edition Delivery Are you a Monroe Journal subscriber? Sign up to view our weekly e-editions each Wednesday with just a click. New Albany Gazette E-Edition Delivery Are you a New Alban...

Message : Required fields NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer REHOVOT, Israel, June 4, 2021 - Purple Biotech Ltd. (Purple Biotech, or the Company) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion a...

Published: May 11, 2021 - Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 - - Dose Escalation Ongoing in Phase 1 Trial of Oral MCL1 Inhibitor PRT1419, with Dose Expansion Cohorts on Track to be Added in 2H21 - WILMINGTON, Del., May 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD)...

More from AP

Press release content from Business Wire. The AP news staff was not involved in its creation. PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights March 15, 2021 GMT MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--Mar 15, 2021-- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the...

Introduction Pleading requirements in federal courts, particularly in securities class action cases, have become increasingly difficult, if not impossible, to satisfy. On December 30, 2020, a U.S. district court in California granted the motion of the biopharmaceutical company, Nektar Therapeutics, Inc. (“Nektar” or “Company”) 1 and its named officers (collectively, “Defendants”) to dismiss Plaintiffs’ second-amended securities fraud complaint (“Complaint”) by means of an opin...